2023-01-01 2023-12-31 false Capium Accounts Production 1.1 12293601 2023-01-01 2023-12-31 12293601 bus:AbridgedAccounts 2023-01-01 2023-12-31 12293601 bus:FRS102 2023-01-01 2023-12-31 12293601 bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 12293601 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 12293601 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 12293601 2023-01-01 2023-12-31 12293601 2023-12-31 12293601 bus:RegisteredOffice 2023-01-01 2023-12-31 12293601 core:WithinOneYear 2023-12-31 12293601 core:AfterOneYear 2023-12-31 12293601 1 2023-01-01 2023-12-31 12293601 bus:Director1 2023-01-01 2023-12-31 12293601 bus:Director1 2023-12-31 12293601 bus:Director1 2021-12-01 2022-12-31 12293601 2021-12-01 12293601 bus:LeadAgentIfApplicable 2023-01-01 2023-12-31 12293601 2021-12-01 2022-12-31 12293601 2022-12-31 12293601 core:WithinOneYear 2022-12-31 12293601 core:AfterOneYear 2022-12-31 12293601 bus:EntityAccountantsOrAuditors 2021-12-01 2022-12-31 12293601 core:ComputerEquipment 2023-01-01 2023-12-31 12293601 core:ComputerEquipment 2023-12-31 12293601 core:ComputerEquipment 2022-12-31 12293601 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-12-31 12293601 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2022-12-31 12293601 core:CostValuation core:Non-currentFinancialInstruments 2023-12-31 12293601 core:CostValuation core:Non-currentFinancialInstruments 2022-12-31 12293601 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-12-31 12293601 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2023-12-31 12293601 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2023-12-31 12293601 core:Non-currentFinancialInstruments 2023-12-31 12293601 core:Non-currentFinancialInstruments 2022-12-31 12293601 core:ShareCapital 2023-12-31 12293601 core:ShareCapital 2022-12-31 12293601 core:SharePremium 2023-12-31 12293601 core:SharePremium 2022-12-31 12293601 core:RetainedEarningsAccumulatedLosses 2023-12-31 12293601 core:RetainedEarningsAccumulatedLosses 2022-12-31 12293601 dpl:Item1 2023-01-01 12293601 dpl:Item1 2023-12-31 12293601 dpl:Item1 2021-12-01 12293601 dpl:Item1 2022-12-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 12293601
England and Wales

 

 

 

AKRIVIA BIOMEDICS LIMITED



Abridged Accounts
 


Period of accounts

Start date: 01 January 2023

End date: 31 December 2023

AKRIVIA BIOMEDICS LIMITED
Contents Page
For the year ended 31 December 2023
Report to the directors on the preparation of the unaudited statutory accounts of AKRIVIA BIOMEDICS LIMITED for the year ended 31 December 2023.
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of AKRIVIA BIOMEDICS LIMITED for the year ended 31 December 2023 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/.
This report is made solely to the Board of Directors of AKRIVIA BIOMEDICS LIMITED, as a body, in accordance with the terms of our engagement letter dated 23 September 2025. Our work has been undertaken solely to prepare for your approval the accounts of AKRIVIA BIOMEDICS LIMITED and state those matters that we have agreed to state to the Board of Directors of AKRIVIA BIOMEDICS LIMITED, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than AKRIVIA BIOMEDICS LIMITED and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that AKRIVIA BIOMEDICS LIMITED has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of AKRIVIA BIOMEDICS LIMITED. You consider that AKRIVIA BIOMEDICS LIMITED is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of AKRIVIA BIOMEDICS LIMITED. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
31 December 2023.



....................................................



23 September 2025
1
 
 		 Notes
 		 2023
£		   2022
£
Fixed assets      
Tangible fixed assets 3 1,533    2,332 
1,533    2,332 
Current assets      
Debtors -    7,500 
Cash at bank and in hand 365    52,915 
365    60,415 
Creditors: amount falling due within one year (25,088)   (25,795)
Net current assets (24,723)   34,620 
 
Total assets less current liabilities (23,190)   36,952 
Net assets (23,190)   36,952 
 

Capital and reserves 		     
Called up share capital 10,225    10,150 
Share premium account 112,275    74,850 
Profit and loss account (145,690)   (48,048)
Shareholders' funds (23,190)   36,952 
 


For the year ended 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 23 September 2025 and were signed by:


-------------------------------
Amit GUPTA
Director
2
General Information
AKRIVIA BIOMEDICS LIMITED is a private company, limited by shares, registered in England and Wales, registration number 12293601, registration address 10 Coldbath Square, LONDON ENGLAND, London, EC1R 5HL.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rate of exchange ruling at the statement of financial position date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All foreign exchange differences are included to the income statement.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 33% Straight Line
2.

Average number of employees

Average number of employees during the year was 2 (2022 : 2).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 January 2023 2,399    2,399 
Additions -    - 
Disposals -    - 
At 31 December 2023 2,399    2,399 
Depreciation
At 01 January 2023 67    67 
Charge for year 799    799 
On disposals -    - 
At 31 December 2023 866    866 
Net book values
Closing balance as at 31 December 2023 1,533    1,533 
Opening balance as at 01 January 2023 2,332    2,332 


3